Next Phase Newsletter

A cross-border venture capital firm with headquarters in Asia and additional offices in USA, is backed by some large pharmaceutical companies. The firm has also launched a new life sciences incubator through which the firm seeks to nurture and advance early-stage therapeutic concepts and technologies. Typically, the firm makes an initial investment ranging from under $1 million to $3-6 million dependent on the company’s stage of development. The firm can allocate up to $16 million over the lifetime of a company. The firm invests in early-stage therapeutic companies worldwide.

The firm only invests in therapeutics, and are primarily focused on companies with preclinical or clinical assets. Within therapeutics, all modalities are of interest. The firm may invest up to 18 months prior to IND, however require that a company has a lead asset that has been characterized. The firm will consider opportunities in any indication area.

The firm invests in teams with experienced, highly motivated teams with a strong background in either life science research or industry.   Remiges Ventures only invests in companies with technology that has the potential to be first in class.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A VC based in Western Europe invests opportunistically within the indications of nephrology, dermatology, urology, CNS/brain and orphan indications. The firm invests in companies from seed-Series A, up to 2M EUR. The firm is currently focused on European companies, but may consider companies based in North America as well.

Within the indications of interest, the firm is willing to consider companies in all sectors, therapeutics, medical devices, diagnostics and digital health. For therapeutic companies, the firm prefers the companies have some preclinical data, and be about a year from initiating clinical trials. For diagnostics companies, The firm prefers the companies be no more than 1 year from commercialization.

The firm can both lead or co-invest, and they may or may not take a board seat, depending on how they can help the company. The firm believes in promoting gender equality, and a large number of their investments are in female-led startups.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A healthcare and technology focused venture capital fund based in USA an Europe only makes equity investments into private companies and has no specific preference in the investment stage. The firm primarily invests in companies that are based in the United States, China, Japan, India, and Europe. The firm is actively seeking new investment opportunities.

The firm is currently looking for new investment opportunities in Biopharmaceutical, Therapeutics and Diagnostics, Medtech, R&D services, and Healthcare IT. Generally the firm invests 65% in Therapeutics, 15%-20% into Medtech/Diagnostics and 15%-20% into HIT/Sevices.

The firm highly prefers to invest in companies with a strong and experienced management team. However, the firm is flexible within specific cases. The firm works with their portfolio companies together to create value for patients and providers.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate investment group that invests strategically on behalf of their parent company uses a variety of structures to work with early stage medical technology companies, including both licensing relationships and equity investments on a case by case basis. The firm is a flexible investor, and the firm’s allocation sizes are wide ranging. The firm invests worldwide.

The firm invests in sectors that are relevant to the parent company’s business groups: Cardiovascular, Restorative Therapies (including spinal implants, neuromodulation treatments for pain and urological disorders, deep brain stimulation, and neurovascular devices), Diabetes, and Minimally Invasive Therapies (including general surgery, gastrointestinal care, pulmonology, and respiratory care and monitoring technologies). The firm is interested in diversifying the parent company’s product and services offerings within all of these groups and also in integrating new fields of information technology and services into the strategic areas, such as IT-enabled patient monitoring and contract management of provider facilities. The firm invests at a range of development stages but generally prefers to work with companies that have obtained clinical data regarding their asset.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.